Bell-shaped curves for prostaglandin-induced modulation of adenylate cyclase: Two mutually opposing effects

European Journal of Pharmacology

Volumn 454, Issue 2-3, 2002, Pages 107-114

  Accomazzo, Maria Rosa ^a   Cattaneo, Sarah ^a   Nicosia, Simonetta ^a   Rovati, G Enrico ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bell shaped curve; G protein; Partial agonist; Pertussis toxin; Prostaglandin; Prostanoid receptor

Indexed keywords

5 CARBACYCLIN; ADENYLATE CYCLASE; CARBACYCLIN DERIVATIVE; ILOPROST; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTANOID; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; ENZYMOLOGY; METABOLISM; RABBIT; REGRESSION ANALYSIS;

ADENYLATE CYCLASE; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; LEAST-SQUARES ANALYSIS; MALE; MESENTERIC ARTERIES; MYOCYTES, SMOOTH MUSCLE; PROSTAGLANDINS; RABBITS;

EID: 0037111176     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02486-X     Document Type: Article

References (27)

1. Ariëns E.J. Affinity and intrinsic activity in the theory of competitive inhibition. Arch. Int. Pharmacodyn. Ther. 99:1954;32-49.
2. Ashby B. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities. Mol. Pharmacol. 36:1989;866-873.
3. Ashby B. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets. Mol. Pharmacol. 38:1990;46-53.
4. Clark A.J. General pharmacology. Handbuch der experimentellen Parmakologie. vol. Band IV:1937;Springer-Verlag, Berlin.
5. Coleman R.A., Smith W.L., Narummiya S. VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
6. Corsini A., Folco G.C., Fumagalli R., Nicosia S., Noe M.A., Oliva D. (5Z)-Carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br. J. Pharmacol. 90:1987;255-261.
7. De Lean A., Munson P.J., Rodbard D. Multi-subsite receptors for multivalent ligands. Application to drugs, hormones, and neurotransmitters. Mol. Pharmacol. 15:1979;60-70.
8. Draper N.R., Smith H. Applied Regression Analysis. 1966;Wiley, New York, NY.
9. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3:1966;21-55.
10. Gilman A.G. G proteins and dual control of adenylate cyclase. Cell. 36:1984;577-579.
11. Katsuyama M., Sugimoto Y., Namba T., Irie A., Negishi M., Narumiya S., Ichikawa A. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 344:1994;74-78.
12. Kenakin T. Agonist-receptor efficacy: II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16:1995;232-238.
13. Kenakin T. Protean agonists. Keys to receptor active states? Ann. N. Y. Acad. Sci. U. S. A. 812:1997;116-125.
14. Lombroso M., Nicosia S., Paoletti R., Whittle B.J., Moncada S., Vane J.R. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins. 27:1984;321-333.
15. Milligan G. Mechanisms of multifunctional signalling by G protein-linked receptors. Trends Pharmacol. Sci. 14:1993;239-244.
16. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263:1976;663-665.
17. Namba T., Sugimoto Y., Negishi M., Irie A., Ushikubi F., Kakizuka A., Ito S., Ichikawa A., Narumiya S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature. 365:1993;166-170.
18. Oliva D., Noe A., Nicosia S., Bernini F., Fumagalli R., Whittle B.J., Moncada S., Vane J.R. Prostacyclin-sensitive adenylate cyclase in cultured myocytes: differences between rabbit aorta and mesenteric artery. Eur. J. Pharmacol. 105:1984;207-213.
19. Ortiz-Vega S., Ashby B. Human prostacyclin receptor: cloning and co-expression with EP3 prostaglandin receptor. Adv. Exp. Med. Biol. 433:1997;235-238.
20. Ross R. The smooth muscle cell: II. Growth of smooth muscle in culture and formation of elastic fibers. J. Cell Biol. 50:1971;172-186.
21. Rovati G.E., Nicosia S. Lower efficacy: interaction with an inhibitory receptor or partial agonism? Trends Pharmacol. Sci. 15:1994;140-144.
22. Rovati G.E., Nicosia S. Verification of a mathematical model used to explain bell-shaped concentration-response curves. Trends Pharmacol. Sci. 15:1994;321.
23. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:1974;541-548.
24. Siegl A.M., Smith J.B., Silver M.J., Nicolaou K.C., Ahern D. Selective binding site for [3H]prostacyclin on platelets. J. Clin. Invest. 63:1979;215-220.
25. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. 11:1956;379-393.
26. Szabadi E. A model of two functionally antagonistic receptor populations activated by the same agonist. J. Theor. Biol. 69:1977;101-112.
27. Tateson J.E., Moncada S., Vane J.R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 13:1977;389-397.